Brennan Daniel J.

Brennan Daniel J., EVP and CFO, has demonstrated a clear selling bias in his recent insider trading activity, as evidenced by SEC Form 4 filings. Over the course of 55 transactions across three companies—WAT, MDGL, and BSX—Brennan has sold shares totaling $24,780,951.39, significantly outweighing his total purchases of $3,058,823.81. Notably, his recent trades have been exclusively sales, with four transactions in BSX (Boston Scientific Corporation) between February 12 and February 19, 2025, amounting to substantial sums. For instance, on February 19, 2025, he sold shares valued at $7,086,111.45, followed by additional sales on February 18 totaling $1,531,365.99 and $301,818.08. These transactions were accompanied by smaller derivative dispositions, such as the exercise of options and the sale of acquired shares, which collectively contributed to the overall pattern of divestment. Brennan’s activity in BSX dominates his recent trading history, with no reported purchases in the company during this period. While he has also been involved in transactions involving WAT and MDGL, these appear to be primarily derivative-related, with no disclosed monetary value in the filings. The absence of recent buys and the concentration of sales in BSX suggest a strategic reduction in his holdings in this particular company. This pattern aligns with his broader trading history, which emphasizes selling over buying, particularly in high-value transactions. The data underscores a consistent trend of divestment, particularly in BSX, as Brennan continues to reduce his stake in the company.